Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 17/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.97 |
| ▸ | ATM | Q13315 | 3/20 | 0.97 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | SREBF1 | P36956 | 2/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fatostatin SCHEMBL29458338 | 1.00 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| Fatostatin SCHEMBL25327929 | 0.99 | MAPT (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL19758233 | 0.95 | SREBF2 (0.90) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4279559 | 0.89 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4293604 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4290927 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4285116 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4286504 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4292296 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4283881 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414626-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-28 | — | — | US | claimed |
| US-11504390-B2 | Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2022-11-22 | — | — | US | claimed |
| WO-2022120197-A1 | COMBINATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS AND STEROL REGULATORY ELEMENT-BINDING PROTEIN INHIBITORS FOR USES IN CANCER THERAPIES | EMORY UNIVERSITY (US) | 2022-06-09 | — | — | WO | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022082078-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-21 | — | — | WO | claimed |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-10 | — | — | US | claimed |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-03 | — | — | US | claimed |
| US-8207196-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-26 | — | — | US | claimed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | claimed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | claimed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | claimed |
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | disclosed |
| US-12048694-B2 | Coordinated metabolic reprogramming in response to productive viral infections | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230414626-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-28 | — | — | US | disclosed |
| US-20230263821-A1 | Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-08-24 | — | — | US | disclosed |
| WO-2010092153-A1 | NEW SUBSTITUTED TETRAHYDRONAPTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048694-B2 | Coordinated metabolic reprogramming in response to productive viral infections | MAVS, ATF4, PC | SREBF2 28/4885MAPT 2780/4885ATM 1642/4885 |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885MAPT 3510/4885ATM 1753/4885 |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885MAPT 3510/4885ATM 1753/4885 |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 32/4885MAPT 3438/4885ATM 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.